



FOR IMMEDIATE RELEASE

MEDIA CONTACT:
Amanda McLafferty
+1.312.673.5825

NIH Director, Dr. Francis Collins, to Receive Lifetime Achievement Award at Mid-Atlantic Bio Conference

WASHINGTON (September 30, 2010)— Francis Collins, Ph.D., M.D., Director of the National Institutes of Health (NIH), will be recognized for his lifetime achievements in biomedical research and human services at the upcoming [2010 Mid-Atlantic Bio Conference](#), held October 27-29 at the North Bethesda Marriott Convention Center in Bethesda, Md.

Born and educated in Virginia and famous for his work as director of the National Human Genome Research Institute at the NIH in Maryland, Dr. Collins is renowned as one of the leading physician-scientists in the world. Due to his vast scientific achievements and deep roots in the region, Mid-Atlantic Bio is recognizing his career with the inaugural Lifetime Achievement Award during the opening reception of the Conference to be held at NIH on October 27.

“The establishment and funding of an additional nine Clinical and Translational Science Awards (CTSAs) this year exemplifies his commitment to advancing scientific collaboration as a means to improve human health and wellbeing,” said Virginia Biotechnology Association Executive Director, Mark A. Herzog. “We are pleased to have Dr. Collins be a part of our event and honor him with the Lifetime Achievement Award.”

Now in its sixth year, Mid-Atlantic Bio is the only globally-focused, yet regionally-based, event to combine components of a bioscience industry convention with an investor conference under one roof. More than 800 national and international industry leaders, government representatives, executives, industry and academic researchers, investors, entrepreneurs, and professional services firms will gather to promote networking, business expansion, and technical-knowledge sharing. Home to industry-critical regulatory and research agencies; federal policymaking; and business and scientific centers of excellence, the Mid-Atlantic is a unique center for the global bioscience industry.

Conference Sessions:

Designed to be a platform that brings together science, company builders, commercial interests and collaborators, capital sources, and federal and regulatory thought-leaders, the [2010 program](#) includes a variety of important industry topics—ranging from the latest in policy and regulatory matters, business and financing opportunities, and CEO War Stories to advances in science and technology—and showcases exciting companies from the biosciences field. A few of the highlighted sessions include:

- Building a Workforce Culture Around Commercialization
- Corporate Venture and Early Stage Partnerships
- New Science Technologies: Regional Successes
- Drugs and Devices: Reimbursement in a Post-Healthcare Reform World
- Capital Eco-Systems: Formation and International Markets
- An Insider's View on Washington
- Synthetic Biology – Applications and Implications
- Accessing the Regulatory Risk: Your Path to Approval
- CEO War Stories: A Roundtable
- Plenary presentations by John Castellani, President and CEO of PhRMA, James Greenwood, President and CEO of BIO, John F. Crowley, JD, MBA, Chairman and CEO of Amicus Therapeutics; Frederick Frank, Vice Chairman, Peter J. Solomon Company; Martine A. Rothblatt, PhD, JD, MBA, Chairman and CEO of United Therapeutics Corporation; Joshua M. Sharfstein, MD, Principal Deputy Commissioner, U.S. Food and Drug Administration; and H. Thomas Watkins, President and CEO, Human Genome Sciences

Company Presentations:

Each year at Mid-Atlantic Bio, a number of life science companies are [chosen to present](#) before an audience of capital sources, including corporate business development professionals, peer scientists and company leaders, venture capitalists, angel investors, and various other qualified financing sources along with important industry professionals and potential strategic partners.

BioMatch:

Mid-Atlantic Bio's signature networking program, [BioMatch](#), is designed specifically for the life sciences and biotech industries, and provides registered attendees access to advanced partnering software that facilitates personalized, one-on-one meetings between the leading bioscience organizations and industry leaders.

Partial List of Conference Sponsors:

Cooley LLP, Hogan Lovells US LLP, Grant Thornton LLP, MedImmune, Wilson Sonsini Goodrich & Rosati, E&Y, BioMed Realty Trust, Inc., Alexandria Real Estate Equities, Inc., Janelia Farms Research Campus of Howard Hughes Medical Institute, NIH Federal Credit Union, George Mason University, Virginia Tech, Deloitte & Touche LLP, H.I.G. BioVentures, Intersouth Partners, New Enterprises Associates, Oxford Finance, TEDCO, Third Security, LLC

ABOUT MID-ATLANTIC BIO

The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland (TCM), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit www.midatlanticbio.org.

###